Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

1.640 -0.020 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,325
Open 1.640
Bid (Size) 1.600 (3)
Ask (Size) 1.900 (1)
Prev. Close 1.660
Today's Range 1.595 - 1.670
52wk Range 1.000 - 3.830
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immuneering Corporation Announces Grant of Inducement Award
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire

Performance

YTD
-25.8%
-25.8%
1 Month
-1.8%
-1.8%
3 Month
-27.1%
-27.1%
6 Month
-34.1%
-34.1%
1 Year
-40.4%
-40.4%

More News

Read More
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
From Immuneering Corporation
Via GlobeNewswire
Why Is Immuneering Stock Trading Higher On Tuesday?
Via Benzinga
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Maximize Your Trades: Pre-Market Insights And Key Stock Breakdowns
Via Talk Markets
Topics ETFs Stocks / Equities
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
From Immuneering Corporation
Via GlobeNewswire
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
Via Talk Markets
Topics Stocks / Equities
Immuneering Launches Pancreatic Cancer Advisory Board
From Immuneering Corporation
Via GlobeNewswire
Top Trade Picks Of The Day: Don’t Miss These Market Movers
Via Talk Markets
Topics Stocks / Equities
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
From Immuneering Corporation
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Via Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
Via Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Via Benzinga
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 1.640
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 03/28/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.